Persistent Asset Partners Ltd Purchases Shares of 6,330 Ascendis Pharma A/S $ASND

Persistent Asset Partners Ltd acquired a new position in shares of Ascendis Pharma A/S (NASDAQ:ASND) in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 6,330 shares of the biotechnology company’s stock, valued at approximately $1,258,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Allianz Asset Management GmbH boosted its position in Ascendis Pharma A/S by 144.7% during the 2nd quarter. Allianz Asset Management GmbH now owns 9,300 shares of the biotechnology company’s stock worth $1,605,000 after acquiring an additional 5,500 shares during the last quarter. R Squared Ltd bought a new stake in shares of Ascendis Pharma A/S in the second quarter worth $209,000. Envestnet Asset Management Inc. boosted its holdings in Ascendis Pharma A/S by 83.4% during the second quarter. Envestnet Asset Management Inc. now owns 21,730 shares of the biotechnology company’s stock worth $3,751,000 after purchasing an additional 9,879 shares during the last quarter. Y Intercept Hong Kong Ltd bought a new position in Ascendis Pharma A/S in the second quarter valued at $682,000. Finally, Hantz Financial Services Inc. grew its position in Ascendis Pharma A/S by 291.1% in the second quarter. Hantz Financial Services Inc. now owns 352 shares of the biotechnology company’s stock valued at $61,000 after purchasing an additional 262 shares in the last quarter.

Ascendis Pharma A/S Stock Up 1.5%

Shares of ASND stock opened at $230.21 on Friday. The firm has a market capitalization of $14.27 billion, a price-to-earnings ratio of -52.32 and a beta of 0.44. The stock has a fifty day moving average of $216.49 and a 200 day moving average of $206.37. Ascendis Pharma A/S has a 52 week low of $124.06 and a 52 week high of $242.00.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings data on Wednesday, February 11th. The biotechnology company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.58). The business had revenue of $290.38 million for the quarter, compared to analyst estimates of $285.35 million. Equities research analysts anticipate that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts have commented on ASND shares. Barclays began coverage on shares of Ascendis Pharma A/S in a research report on Tuesday, January 27th. They set an “overweight” rating and a $342.00 price target on the stock. Wedbush upped their target price on Ascendis Pharma A/S from $240.00 to $273.00 and gave the stock an “outperform” rating in a report on Thursday, February 12th. Wolfe Research began coverage on Ascendis Pharma A/S in a research report on Tuesday, November 18th. They set a “peer perform” rating and a $255.00 price target for the company. Cantor Fitzgerald restated an “overweight” rating on shares of Ascendis Pharma A/S in a research note on Wednesday, November 26th. Finally, Bank of America boosted their price target on Ascendis Pharma A/S from $246.00 to $260.00 and gave the stock a “buy” rating in a research report on Friday, January 30th. Two analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $284.00.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.